Recent Articles

Study Uses Open Data to Analyze “Normal” Tissue Near Tumors

| October 23, 2017 | 0 Comments

Study Uses Open Data to Analyze “Normal” Tissue Near Tumors The tissue immediately surrounding a tumor may not be normal, even if it appears normal under the microscope, according to an analysis of data from two genomic databases suggests.See Original Article

Continue Reading

Nivolumab Receives Accelerated Approval from FDA for Advanced Liver Cancer

| October 20, 2017 | 0 Comments

Nivolumab Receives Accelerated Approval from FDA for Advanced Liver Cancer The FDA has granted accelerated approval to the immunotherapy drug nivolumab (Opdivo®) for patients with advanced liver cancer who have previously been treated with the targeted therapy sorafenib (Nexavar®).See Original Article

Continue Reading

Studies Identify Therapies That May Delay Melanoma Recurrence after Surgery

| October 19, 2017 | 0 Comments

Studies Identify Therapies That May Delay Melanoma Recurrence after Surgery Two recent clinical trials have identified treatments that may delay cancer from returning in some patients with melanoma. Patients in both trials had advanced melanoma that was surgically removed, and each trial tested different forms of post-surgical, or adjuvant, therapy.See Original Article

Continue Reading

Copanlisib Approved for Follicular Lymphoma

| October 16, 2017 | 0 Comments

Copanlisib Approved for Follicular Lymphoma FDA has granted accelerated approval to copanlisib (Aliquopa®) for the treatment of patients with follicular lymphoma, a form of non-Hodgkin lymphoma.See Original Article

Continue Reading

Pembrolizumab Secures FDA Approval in Stomach Cancer

| October 12, 2017 | 0 Comments

Pembrolizumab Secures FDA Approval in Stomach Cancer The FDA has granted accelerated approval to the immunotherapy drug pembrolizumab (Keytruda®) for use in patients with advanced gastric (stomach) cancer that is PD-L1 positive.See Original Article

Continue Reading

Extensive Lymph Node Removal Doesn't Improve Survival in Some Women with Early-Stage Breast Cancer

| October 10, 2017 | 0 Comments

Extensive Lymph Node Removal Doesn't Improve Survival in Some Women with Early-Stage Breast Cancer Long-term results from a large clinical trial confirm that, for some women with early-stage breast cancer who have lumpectomy as their surgical treatment, a less extensive lymph node biopsy approach is sufficient.See Original Article

Continue Reading

NCI-DOE Collaboration Paving Way for Large-Scale Computational Cancer Science

| October 9, 2017 | 0 Comments

NCI-DOE Collaboration Paving Way for Large-Scale Computational Cancer Science NCI and the Department of Energy have entered into a collaboration to develop a plan to use large-scale computing to influence cancer science and, ultimately, clinical treatment.See Original Article Ibrutinib Becomes First FDA-Approved Drug for Chronic Graft-Versus-Host Disease A drug used to treat several blood cancers, […]

Continue Reading

A Message from Dr. Frank McCormick

| October 7, 2017 | 0 Comments

A Message from Dr. Frank McCormick Frank McCormick, pioneering RAS researcher and former head of the UCSF cancer center, describes the problem with RAS cancers and how the NCI RAS Initiative will attack them.See Original Article What Do We Mean By "RAS Pathway"? Frank McCormick, scientific lead of the RAS Initiative, requests input from the […]

Continue Reading

Study Identifies Crucial Characteristic of High-Risk HPV

| October 5, 2017 | 0 Comments

Study Identifies Crucial Characteristic of High-Risk HPV By comparing the genomes of women infected with a high-risk type of human papillomavirus (HPV), researchers have found that a precise DNA sequence of a viral gene is associated with cervical cancer. See Original Article

Continue Reading

Timing and Sequence Critical for Immunotherapy Combination

| October 3, 2017 | 0 Comments

Timing and Sequence Critical for Immunotherapy Combination When given at the same time, two immune checkpoint inhibitors were ineffective against breast cancer growth in mice, a new study found. The combination was more effective and safer if the two inhibitors were given in a specific sequence.See Original Article

Continue Reading